Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results After the Close of Markets on Thursday, March 11, 2021
Assertio Holdings, Inc. (NASDAQ: ASRT) announced that it will release its fourth quarter and full year 2020 financial results on March 11, 2021, after market close. A conference call with management is scheduled for 4:30 p.m. Eastern Time on the same day. Assertio is noted for its differentiated pharmaceutical products in neurology, hospital, and pain and inflammation segments. Investors can access the live webcast and replay via the company’s investor website.
- Scheduled release of Q4 and full year 2020 financial results indicates transparency to investors.
- Management will host a conference call, allowing for direct engagement with investors.
- None.
LAKE FOREST, Ill., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release fourth quarter and full year 2020 financial results on Thursday, March 11, 2021, after the close of markets. Following the release of its financial results, Assertio’s management will host a conference call beginning at 4:30 p.m. eastern time.
Conference Call and Webcast Information
| Date: | Thursday, March 11, 2021 |
| Time: | 4:30 p.m. Eastern Time |
| Dial-in numbers: | 1-877-550-3745 (domestic) |
| 1-281-973-6277 (international) | |
| Replay numbers: | 1-855-859-2056 (domestic) |
| 1-404-537-3406 (international) | |
| Conference number: | 6285078 |
The live webcast and replay may be accessed at https://investor.assertiotx.com/. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. The replay will be available approximately two hours after the call on Assertio’s investor website.
About Assertio
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through business development including licensing, mergers, and acquisitions. To learn more visit www.assertiotx.com.
Investor Contact
Max Nemmers
investor@assertiotx.com
Forward Looking Statements
Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio. All statements other than historical facts may be forward-looking statements and can be identified by words such as “anticipate,” ‘believe,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “imply,” “intend,” “may,” “objective,” “opportunity,” “outlook,” “plan,” “position,” “potential,” “predict,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “would,” “will,” “aim” or other similar expressions that convey the uncertainty of future events or outcomes are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio.
Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks related to the offering. These risks are more fully described in the joint proxy statement/prospectus filed with the SEC in connection with the Merger, Assertio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC, the prospectus supplement relating to the offering and in other filings Assertio makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law. Nothing contained herein constitutes or will be deemed to constitute a forecast, projection or estimate of the future financial performance or expected results of Assertio.
FAQ
When will Assertio release its Q4 and full year 2020 financial results?
What time is the conference call for Assertio's financial results?
How can I access the webcast of Assertio's financial results?
What is Assertio's stock symbol?
